Hypothesis

Chronic cGAS‑STING signaling in aging does not merely produce a mixed inflammatory phenotype; it rewires JAK‑STAT signaling to favor STAT2/IRF9 complexes that recruit epigenetic modifiers, establishing a self‑reinforging transcriptional program that drives multiple hallmarks of aging simultaneously.

Mechanistic Model

1. Persistent mtDNA release activates cGAS‑STING, leading to sustained JAK activation.
2. In aged cells, prolonged JAK phosphorylation favors delayed STAT2 phosphorylation and its pairing with IRF9, forming STAT2/IRF9 heterotrimers that translocate to the nucleus.
3. STAT2/IRF9 directly interacts with DNA methyltransferase DNMT3A and the demethylase TET2, targeting promoters of senescence‑associated secretory phenotype (SASP) genes and suppressors of antioxidant defenses.
4. This results in locus‑specific DNA methylation of protective genes (e.g., SOD2, FOXO3) and hydroxymethylation of pro‑inflammatory ISGs, locking in a pathological expression state.
5. The altered epigenome further increases mitochondrial dysfunction, amplifying mtDNA release and completing a feed‑forward loop that couples innate immune signaling to epigenetic aging.

Testable Predictions

• Inhibiting STAT2/IRF9 interaction (e.g., with a cell‑permeable peptide that blocks STAT2‑IRF9 binding) will reduce SASP factor secretion without compromising STAT1‑dependent antiviral ISG induction in aged human fibroblasts.
• CRISPR‑mediated knock‑in of a STAT2 Y690F mutation (preventing its phosphorylation) in aged mice will decrease DNMT3A recruitment to SASP promoters, leading to demethylation of antioxidant genes and improved tissue function.
• If the epigenetic rewiring is central, simultaneous DNMT3A/TET2 modulation should phenocopy the effects of STAT2/IRF9 blockade on multiple aging hallmarks (senescence, stem cell exhaustion, altered intercellular communication).

Potential Experiments

• In vitro: Treat senescent human mesenchymal stem cells with cGAS agonist, then add STAT2/IRF9‑disrupting peptide. Measure p‑STAT1 vs p‑STAT2 levels, ISG profiles (qPCR), SASP cytokines (ELISA), and bisulfite sequencing of SOD2 and IL6 promoters.
• In vivo: Use aged STAT2 Y690F knock‑in mice. Assess grip strength, treadmill endurance, circulating IL‑6, and histone modification marks (ChIP‑seq for H3K27ac) in liver and muscle after 4 months.
• Rescue: overexpress TET2 in STAT2‑deficient aged cells to test whether demethylation of protective genes restores resistance to oxidative stress.

Implications

If validated, this hypothesis reframes aging as a disease of signal‑dependent epigenetic reprogramming rather than a collection of independent damages. It suggests that targeting the STAT2/IRF9‑epigenetic axis could simultaneously ameliorate inflammation, mitochondrial decline, and loss of regenerative capacity, offering a single therapeutic node for multidomain aging intervention.